Defined Financial Planning LLC Takes $384,000 Position in Becton, Dickinson and Company (NYSE:BDX)

Defined Financial Planning LLC purchased a new position in Becton, Dickinson and Company (NYSE:BDX - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 1,700 shares of the medical instruments supplier's stock, valued at approximately $384,000.

Other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC lifted its position in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after buying an additional 877 shares during the period. Phraction Management LLC lifted its position in Becton, Dickinson and Company by 7.2% during the fourth quarter. Phraction Management LLC now owns 47,021 shares of the medical instruments supplier's stock worth $10,668,000 after buying an additional 3,138 shares during the period. Savant Capital LLC lifted its position in Becton, Dickinson and Company by 85.9% during the fourth quarter. Savant Capital LLC now owns 14,628 shares of the medical instruments supplier's stock worth $3,319,000 after buying an additional 6,759 shares during the period. Van ECK Associates Corp lifted its position in Becton, Dickinson and Company by 3.1% during the fourth quarter. Van ECK Associates Corp now owns 14,738 shares of the medical instruments supplier's stock worth $3,344,000 after buying an additional 450 shares during the period. Finally, Proficio Capital Partners LLC purchased a new position in Becton, Dickinson and Company during the fourth quarter worth about $21,607,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Performance

NYSE:BDX traded down $2.40 during trading hours on Friday, reaching $172.06. 2,276,369 shares of the stock were exchanged, compared to its average volume of 1,975,669. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. The firm has a 50 day simple moving average of $183.03 and a 200-day simple moving average of $213.01. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The stock has a market capitalization of $49.31 billion, a P/E ratio of 28.58, a P/E/G ratio of 1.63 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. The company had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.35 billion. During the same quarter last year, the business posted $3.17 EPS. Becton, Dickinson and Company's quarterly revenue was up 4.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Investors of record on Monday, June 9th will be issued a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.42%. The ex-dividend date of this dividend is Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 79.39%.

Wall Street Analyst Weigh In

BDX has been the topic of a number of research reports. Wall Street Zen downgraded Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. William Blair downgraded Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Thursday, May 1st. Raymond James downgraded Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Friday, May 2nd. Barclays cut their price objective on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a report on Tuesday, June 3rd. Finally, Piper Sandler downgraded Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and cut their price objective for the stock from $260.00 to $185.00 in a report on Friday, May 2nd. Eight research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $219.22.

Insider Buying and Selling

In related news, EVP David Shan sold 1,166 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total value of $199,607.54. Following the sale, the executive vice president now owns 4,575 shares of the company's stock, valued at approximately $783,194.25. This trade represents a 20.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 479 shares of the firm's stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total value of $94,497.12. Following the completion of the sale, the executive vice president now directly owns 4,887 shares in the company, valued at approximately $964,107.36. This trade represents a 8.93% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 2,104 shares of company stock valued at $399,675. Insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.